Sandbox Reserved 963: Difference between revisions

Line 2:

==Structure of anti-amyloid-beta Fab WO2 (Form A, P212121)==

~~This is a default text for your page~~ ''''''. ~~Click above on '''edit this page'''~~ to ~~modify. Be careful~~ with ~~the < and > signs~~.

'''Alzheimer's disease (AD)''', is the most common form of dementia. It is a chronic neurodegenerative disease that usually develops slowly and get worse over time, becoming severe enough to interfere with daily tasks. The most common early symptom of Alzheimer's is difficulty remembering recently learned information. As the patient with Alzheimer’s disease ages, many symptoms can appear: speaking problems, language problems, mood swings, disorientation, behavioural issues, and loss of motivation.

~~You may include any references to papers as in: the use~~ of ~~JSmol in Proteopedia <ref>DOI 10~~.~~1002/ijch.201300024</ref> or to~~ the ~~article describing Jmol <ref>PMID~~:~~21638687</ref> to the rescue~~.

Alzheimer's disease (AD), is the most common form of dementia. It is a chronic neurodegenerative disease that usually develops slowly and get worse over time, becoming severe enough to interfere with daily tasks. The most common early symptom of Alzheimer's is difficulty remembering recently learned information. As the patient with Alzheimer’s disease ages, many symptoms can appear: speaking problems, language problems, mood swings, disorientation, behavioural issues, and loss of motivation.

Five medications are currently used to treat the cognitive problems of AD: four are acetylcholinesterase inhibitors (tacrine, rivastigmine, galantamine and donepezil) and the other (memantine) is an NMDA receptor antagonist. The benefit from their use is small. No medication has been clearly shown to delay or halt the progression of the disease.

Five medications are currently used to treat the cognitive problems of AD: four are acetylcholinesterase inhibitors (tacrine, rivastigmine, galantamine and donepezil) and the other (memantine) is an NMDA receptor antagonist.~~[156]~~ The benefit from their use is small.~~[157][158]~~ No medication has been clearly shown to delay or halt the progression of the disease.

Acetylcholinesterase inhibitors such as rivastigmine, tacrine, donepezil and galantamine or, memantine, which is a NMDA receptor antagonist, are used to treat the patients suffering from AD but unfortunately, the benefit from their use is small. It is important to understand that none of these medications stops the disease itself.

Acetylcholinesterase inhibitors such as [rivastigmine], tacrine, donepezil and galantamine or, memantine, which is a NMDA receptor antagonist, are used to treat the patients suffering from AD but unfortunately, the benefit from their use is small. It is important to understand that none of these medications stops the disease itself.

However, many groups of researchers are seeking a solution to this problem and most of them are currently focused on the activity of a small peptide called Amyloid ß.

The known cause of this disease is depicted as the presence of the amyloid plaques found in the brains of Alzheimer patients, which are composed of Amyloid ß (Aß).

Line 19:

Line 15:

Alzheimer's disease (AD), is the most common form of dementia. It is a chronic neurodegenerative disease that usually develops slowly and get worse over time, becoming severe enough to interfere with daily tasks. The most common early symptom of Alzheimer's is difficulty remembering recently learned information. As the patient with Alzheimer’s disease ages, many symptoms can appear: speaking problems, language problems, mood swings, disorientation, behavioural issues, and loss of motivation.

Five medications are currently used to treat the cognitive problems of AD: four are acetylcholinesterase inhibitors (tacrine, rivastigmine, galantamine and donepezil) and the other (memantine) is an NMDA receptor antagonist.~~[156]~~ The benefit from their use is small.~~[157][158]~~ No medication has been clearly shown to delay or halt the progression of the disease.

Five medications are currently used to treat the cognitive problems of AD: four are acetylcholinesterase inhibitors (tacrine, rivastigmine, galantamine and donepezil) and the other (memantine) is an NMDA receptor antagonist. The benefit from their use is small. No medication has been clearly shown to delay or halt the progression of the disease.

Acetylcholinesterase inhibitors such as ~~rivastigmine~~, tacrine, donepezil and galantamine or, memantine, which is a NMDA receptor antagonist, are used to treat the patients suffering from AD but unfortunately, the benefit from their use is small. It is important to understand that none of these medications stops the disease itself.

Acetylcholinesterase inhibitors such as [http://en.wikipedia.org/wiki/Rivastigmine], tacrine, donepezil and galantamine or, memantine, which is a NMDA receptor antagonist, are used to treat the patients suffering from AD but unfortunately, the benefit from their use is small. It is important to understand that none of these medications stops the disease itself.

However, many groups of researchers are seeking a solution to this problem and most of them are currently focused on the activity of a small peptide called Amyloid ß.

The known cause of this disease is depicted as the presence of the amyloid plaques found in the brains of Alzheimer patients, which are composed of Amyloid ß (Aß).

Sandbox Reserved 963: Difference between revisions

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 2: / Line 2: @@
 ==Structure of anti-amyloid-beta Fab WO2 (Form A, P212121)==
 <StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''>
-This is a default text for your page ''''''. Click above on '''edit this page''' to modify. Be careful with the &lt; and &gt; signs.
+'''Alzheimer's disease (AD)''', is the most common form of dementia. It is a chronic neurodegenerative disease that usually develops slowly and get worse over time, becoming severe enough to interfere with daily tasks. The most common early symptom of Alzheimer's is difficulty remembering recently learned information. As the patient with Alzheimer’s disease ages, many symptoms can appear: speaking problems, language problems, mood swings, disorientation, behavioural issues, and loss of motivation.
-You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.
-Alzheimer's disease (AD), is the most common form of dementia. It is a chronic neurodegenerative disease that usually develops slowly and get worse over time, becoming severe enough to interfere with daily tasks. The most common early symptom of Alzheimer's is difficulty remembering recently learned information. As the patient with Alzheimer’s disease ages, many symptoms can appear: speaking problems, language problems, mood swings, disorientation, behavioural issues, and loss of motivation.
+Five medications are currently used to treat the cognitive problems of AD: four are acetylcholinesterase inhibitors (tacrine, rivastigmine, galantamine and donepezil) and the other (memantine) is an NMDA receptor antagonist. The benefit from their use is small. No medication has been clearly shown to delay or halt the progression of the disease.
-Five medications are currently used to treat the cognitive problems of AD: four are acetylcholinesterase inhibitors (tacrine, rivastigmine, galantamine and donepezil) and the other (memantine) is an NMDA receptor antagonist.[156] The benefit from their use is small.[157][158] No medication has been clearly shown to delay or halt the progression of the disease.
-Acetylcholinesterase inhibitors such as rivastigmine, tacrine, donepezil and galantamine or, memantine, which is a NMDA receptor antagonist, are used to treat the patients suffering from AD but unfortunately, the benefit from their use is small. It is important to understand that none of these medications stops the disease itself.
+Acetylcholinesterase inhibitors such as [rivastigmine], tacrine, donepezil and galantamine or, memantine, which is a NMDA receptor antagonist, are used to treat the patients suffering from AD but unfortunately, the benefit from their use is small. It is important to understand that none of these medications stops the disease itself.
 However, many groups of researchers are seeking a solution to this problem and most of them are currently focused on the activity of a small peptide called Amyloid ß.
 The known cause of this disease is depicted as the presence of the amyloid plaques found in the brains of Alzheimer patients, which are composed of Amyloid ß (Aß).
@@ Line 19: / Line 15: @@
 Alzheimer's disease (AD), is the most common form of dementia. It is a chronic neurodegenerative disease that usually develops slowly and get worse over time, becoming severe enough to interfere with daily tasks. The most common early symptom of Alzheimer's is difficulty remembering recently learned information. As the patient with Alzheimer’s disease ages, many symptoms can appear: speaking problems, language problems, mood swings, disorientation, behavioural issues, and loss of motivation.
-Five medications are currently used to treat the cognitive problems of AD: four are acetylcholinesterase inhibitors (tacrine, rivastigmine, galantamine and donepezil) and the other (memantine) is an NMDA receptor antagonist.[156] The benefit from their use is small.[157][158] No medication has been clearly shown to delay or halt the progression of the disease.
+Five medications are currently used to treat the cognitive problems of AD: four are acetylcholinesterase inhibitors (tacrine, rivastigmine, galantamine and donepezil) and the other (memantine) is an NMDA receptor antagonist. The benefit from their use is small. No medication has been clearly shown to delay or halt the progression of the disease.
-Acetylcholinesterase inhibitors such as rivastigmine, tacrine, donepezil and galantamine or, memantine, which is a NMDA receptor antagonist, are used to treat the patients suffering from AD but unfortunately, the benefit from their use is small. It is important to understand that none of these medications stops the disease itself.
+Acetylcholinesterase inhibitors such as [http://en.wikipedia.org/wiki/Rivastigmine], tacrine, donepezil and galantamine or, memantine, which is a NMDA receptor antagonist, are used to treat the patients suffering from AD but unfortunately, the benefit from their use is small. It is important to understand that none of these medications stops the disease itself.
 However, many groups of researchers are seeking a solution to this problem and most of them are currently focused on the activity of a small peptide called Amyloid ß.
 The known cause of this disease is depicted as the presence of the amyloid plaques found in the brains of Alzheimer patients, which are composed of Amyloid ß (Aß).